An interventional study of MRI and Biochemical Analysis in Diabetic Kidney Disease (DKD), sponsored by Mario Negri Institute for Pharmacological Research. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Mario Negri Institute for Pharmacological Research · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Diabetic Nephropathies with a site in Denmark — 6 open to participants now, 6 under way, none of them phase 3. Diabetic Nephropathies · Denmark.
Among the 42 studies in Diabetic Nephropathies with a site in Denmark, this one is the 13th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 42nd registered.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →6 of the 42 studies in Diabetic Nephropathies with a site in Denmark are open now. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 40+
River 3 Renal Corp. · Sites in Denmark
Ages 18+
Herlev Hospital · Sites in Denmark
Ages 18–120
University Medical Center Groningen · Sites in Denmark, Finland
Ages 18–64
Steno Diabetes Center Copenhagen · Sites in Denmark, United Kingdom
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 15 · Phase 3 5 · Phase 4 10
First in 1993; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 61 across the 36 interventional studies, 144 across the 6 observational. Of the 31 that completed or were terminated, 8 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 42 have an industry lead sponsor. The 10 most frequent:
Mario Negri Institute for Pharmacological Research is the lead sponsor of 161 studies on the registry; 38 are open to participants now.
Mario Negri Institute for Pharmacological Research has 2 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Nephropathies with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06600412River 3 Renal Corp.The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. | 2027-04-01 |
| NCT06147232Steno Diabetes Center CopenhagenPrevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Diabetic Nephropathies with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre and multi-national non-pharmacological, uncontrolled interventional study conducted in a clinical practice setting in DKD patients with CKD stages G1 to G3 with moderate or severe risk of renal function decline in chronic treatment with SGLT2i.
The main aim of the study is to assess the independent role of baseline individual mpMRI markers (hemodynamic, oxygenation, microstructure, perfusion, and fat fraction) and biochemical markers of MMP-related pathways (MMP-10 and TIMP-1) in the prediction of chronic eGFR decline over 18 months in the above mentioned patients who are on chronic SGLT2i therapy.
Recent years have seen an exponential increase in the incidence and prevalence of chronic kidney disease (CKD). Diabetes Mellitus is the leading cause of CKD. Diabetic kidney disease (DKD) is clinically defined by the presence of reduced kidney function and/or increased albuminuria for at least three months in patients with diabetes. However, not all patients with diabetes develop DKD and not all patients with DKD follow the same trajectory. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently shown significant nephroprotective benefits, making them a first-line therapy in DKD. Although the mechanisms underlying SGLT2i nephroprotection are not fully understood, preliminary data suggest a long-term benefit on metabolic, haemodynamics, and/or kidney injury pathways. SGLT2i have also been shown to be nephroprotective in mouse models, attenuating renal fibrosis in diabetes. These promising results highlight the potential of SGLT2i to avert severe CKD-related events through early intervention, particularly in patients at higher risk of progression. However, clinical, and genetic factors may influence response to SGLT2i in patients with comorbid conditions and already receiving antidiabetic and antihypertensive drugs. Therefore, within a personalised medicine approach, it would be essential to early identify DKD patients with fast progressive decline in renal function, associated with increased morbidity and mortality, who may benefit the most from SGLT2i therapy. To achieve this, biomarkers with heightened specificity and sensitivity to disease progression and response to treatment are urgently needed.
Renal multiparametric MRI (mpMRI) has recently shown great potential to investigate renal structure, microstructure, and function, facilitating the diagnosis and monitoring of CKD progression and response to treatment. Recent studies showed the ability of decreased renal blood flow - assessed by arterial spin labelling (ASL) MRI - in detecting subclinical renal involvement in patients with type 2 diabetes. Blood oxygenation level dependent (BOLD)-MRI showed an acute effect on renal cortical oxygenation in response to SGLT2i treatment in type I diabetic patients with albuminuria. mpMRI shows potential to investigate and quantify renal and perirenal adipose tissue (fat fraction), that is thought to play a significant role on the renal involvement in diabetes and obesity. mpMRI has also shown its ability to monitor the effects of SGLT2i in type 2 diabetes.
Moreover, the hallmark of DKD pathogenesis is excessive accumulation of extracellular matrix (ECM) leading to thickening of the glomerular and tubular basement membranes, followed by mesangial expansion, sclerosis, and tubulointerstitial fibrosis. Dysregulated balance between levels of matrix metalloproteases (MMPs, involved in ECM degradation and hydrolysis) and their tissue inhibitors (TIMP) has been found in DKD patients, and altered serum and urine TIMP-1 levels have been linked with worsening glomerular lesions. MMP-10 null diabetic mice presented fewer mesangial expansion, renal macrophage infiltration and renal function impairment. These findings may support a deleterious kidney effect of MMP-10 in DKD.
To confirm and expand these single-centre findings, a more in-depth analysis of pathogenic mechanisms and a more accurate risk stratification are required in order to personalise the clinical management of DKD.
The PERSONALISE-DKD clinical study aims to use advanced biochemical and imaging biomarkers to characterize DKD patients at moderate or severe risk of renal disease progression who may get the greatest benefit from future clinical trials and targeted healthcare management interventions, potentially contributing to a change in the current clinical approach to a disease that represents the leading cause of advanced CKD.
The criteria were revised on the registry on Nov 19, 2026. See what changed
Inclusion Criteria (to be eligible to participate in this trial, an individual must meet all the following criteria):
Exclusion Criteria (an individual who meets any of the following criteria will be excluded from participation in this trial):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult Diabetic Kidney Disease (DKD) patients with CKD stages G1 to G3 at moderate or severe risk of renal disease progression, receiving ongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 month and no longer than 1 year, and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific contraindications for this medication).
Procedure: MRI and Biochemical Analysis
Adult patients with diabetic kidney disease (DKD), CKD stages G1-G3, at moderate or severe risk of renal disease progression, who are SGLT2i-naïve at the time of screening and have been prescribed SGLT2i therapy as part of routine clinical practice prior to study enrollment.
Procedure: MRI and Biochemical Analysis
Multiparametric non-contrast enhanced renal MRI and biochemical analysis to investigate MMP-related pathways (MMP-10 and TIMP-1 serum levels)
Estimated glomerular filtration rate (eGFR)
EGFR estimation by CKD-EPI and EKFC equations (ml/min)
Time frame: At day 0, at 1 month and at 18 months
Matrix metalloproteases (MMPs) and their tissue inhibitors (TIMP)
Serum levels of MMP-10 and TIMP-1 will be assessed in blood samples by commercial ELISA kits, according to the manufacturer's instructions (pg/ml)
Time frame: At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Total kidney, cortical and medullary volumes (in mL)
Time frame: At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Renal tissue oxygenation obtained by measuring the R2\* relaxation rate (in 1/ms)
Time frame: At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Apparent diffusion coefficient (in cm2/s)
Time frame: At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Renal tissue perfusion (in mL/100mL/min)
Time frame: At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Renal blood flow (in mL/min)
Time frame: At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
T1 and T2 relaxation times (in ms)
Time frame: At day 0, at 1 month and at 18 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.
Of 50 non-industry interventional studies with no phase under Diabetic Nephropathies, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 16 months is below that.
Counting every sponsor, half of 51 studies reached it within 23 months; a quarter within 11 and three quarters within 37.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Feb 2026 → Dec 2026, primary completion Aug 2027 → Apr 2028 and completion Aug 2027 → Apr 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mario Negri Institute for Pharmacological Research →